: Iron Deficiency Anemia (IDA) is a leading cause of anemia in Inflammatory Bowel disease (IBD). IDA affects quality of life (QoL) and lead to developmental and cognitive abnormalities. Diagnosis of IDA in IBD is complicated as biochemical tests available at present cannot help distinguish between IDA and anemia of chronic disease. Soluble transferrin receptor ferritin index has been gaining popularity as it can diagnose IDA in presence of chronic inflammation. ECCO guidelines recommend a Hb increase of >2 g/dL and a TfS of >30% within 4 weeks as adequate therapeutic response. IV iron is preferred over oral iron as it bypasses gastrointestinal tract, rapidly increases haemoglobin, and is not associated with intestinal inflammation. Our aim in this review is to provide apathway for physicians to help them diagnose and appropriately treat IDA in IBD.: In this review article, we have discussed current diagnosis and treatment in detail and have proposed new directions on how future research can help manage IDA in IBD effectively.: Understanding the pathogenesis of IDA in IBD will further lead to exploring new potential diagnostic tests and treatment regimens for effective management of IDA in IBD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/17474124.2021.1900730 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluating the cost-utility of ferric derisomaltose versus ferric carboxymaltose in patients with inflammatory bowel disease and iron deficiency anaemia in Norway.
J Med Econ
December 2024
Covalence Research Ltd, Harpenden, UK.
Aims: Iron deficiency anemia (IDA) is among the most common extraintestinal sequelae of inflammatory bowel disease (IBD). Intravenous iron is often the preferred treatment in patients with active inflammation with or without active bleeding, iron malabsorption, or intolerance to oral iron. The aim of the present study was to evaluate the cost-utility of ferric derisomaltose (FDI) versus ferric carboyxymaltose (FCM) in patients with IBD and IDA in Norway.
View Article and Find Full Text PDFA Cost-Utility Analysis of Ferric Derisomaltose Versus Ferric Carboxymaltose in Patients with Iron Deficiency Anemia in China.
Adv Ther
November 2024
Covalence Research Ltd, Rivers Lodge, West Common, Harpenden, AL5 2JD, UK.
Article Synopsis
- Intravenous (IV) iron is crucial for treating iron deficiency anemia (IDA) when oral iron isn't effective or safe; FDI and FCM are two IV formulations that have been compared for safety and cost-effectiveness.* -
- A simulation model in China revealed that patients using FDI required fewer infusions and incurred lower overall costs compared to FCM, saving about RMB 206 on iron procurement and administration.* -
- FDI not only resulted in cost savings but also improved patients' quality of life by reducing the incidence of hypophosphatemia-related fatigue, making it the preferred treatment option over FCM.*
A Prospective Observational Study Analyzing the Diagnostic Value of Hepcidin-25 for Anemia in Patients with Inflammatory Bowel Diseases.
Int J Mol Sci
March 2024
Medical Faculty of the Military Medical Academy, University of Defence, 11 000 Belgrade, Serbia.
Iron deficiency (IDA) and chronic disease (ACD) anemia are complications of inflammatory bowel diseases (IBDs). Therapeutic modalities in remission and active IBD depend on the type of anemia. This study evaluated the link between hepcidin-25, proinflammatory cytokines, and platelet activation markers as biomarkers of anemia and inflammation in active IBD and remission.
View Article and Find Full Text PDFInpatient management of iron deficiency anemia in pediatric patients with inflammatory bowel disease: A single center experience.
World J Clin Pediatr
March 2024
Center for Inflammatory Bowel Disease, Boston Children's Hospital, Boston, MA 02115, United States.
Background: Screening for iron deficiency anemia (IDA) is important in managing pediatric patients with inflammatory bowel disease (IBD). Concerns related to adverse reactions may contribute to a reluctance to prescribe intravenous (IV) iron to treat IDA in this population.
Aim: To track the efficacy and safety of IV iron therapy in treating IDA in pediatric IBD patients admitted to our center.
Potential Diagnostic Role of Hepcidin in Anemic Patients Affected by Inflammatory Bowel Disease: A Systematic Review.
Diagnostics (Basel)
February 2024
Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy.
Background: Anemia is the main extraintestinal comorbidity of Inflammatory Bowel Disease (IBD). Differentiating the type of anemia in these disorders is still a challenge. Hepcidin could be a promising biomarker to identify iron deficiency anemia (IDA), anemia of chronic disease (ACD) and the concomitant presence of both IDA and ACD.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!